Clinical Guide to ABO-Incompatible Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 8, 2013, Pages 1152-1158

  Booth, Garrett S ^a   Gehrie, Eric A ^a   Bolan, Charles D ^b   Savani, Bipin N ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood group; Hemolysis; Stem cell; Transfusion; Transplant

Indexed keywords

BLOOD GROUP ANTIGEN;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION REACTION; CHRONIC GRAFT VERSUS HOST DISEASE; DONOR SELECTION; ENGRAFTMENT; GRAFT RECIPIENT; HEMOLYSIS; HLA MATCHING; HUMAN; INCIDENCE; OVERALL SURVIVAL; PREVENTION AND CONTROL; PURE RED CELL ANEMIA; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; THROMBOCYTE TRANSFUSION;

BLOOD GROUP; HEMOLYSIS; STEM CELL; TRANSFUSION; TRANSPLANT;

ABO BLOOD-GROUP SYSTEM; BLOOD GROUP INCOMPATIBILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84880506434     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.03.018     Document Type: Review

References (75)

1. Bakker E., Pearson P.L., Meera Khan P., et al. Orientation of major histocompatibility (MHC) genes relative to the centromere of human chromosome 6. Clin Genet 1979, 15:198-202.
2. Campbell R.D., Trowsdale J. Map of the human MHC. Immunol Today 1993, 14:349-352.
3. Sieff C., Bicknell D., Caine G., et al. Changes in cell surface antigen expression during hemopoietic differentiation. Blood 1982, 60:703-713.
4. Yamamoto F. Review: ABO blood groups system-ABH oligosaccharide antigens, anti-A and anti-B, A and B glycosyltransferases, and ABO genes. Immunohematology 2004, 20:3-22.
5. Kominato Y., Hata Y., Matsui K., et al. Transcriptional regulation of thehuman ABO histo-blood group genes is dependent on the N boxupstream of the proximal promoter. Transfusion 2004, 44:1741-1749.
6. Rowley S.D., Donato M.L., Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant 2011, 46:1167-1185.
7. Kimura F., Sato K., Kobayashi S., et al. Impact of ABO-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica 2008, 93:1686-1693.
8. Broxmeyer H.E., Douglas G.W., Hangoc G., et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. PNAS 1989, 86:3828-3832.
9. Seebach J.D., Stussi G., Passweg J.R., et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant 2005, 11:1006-1013.
10. Michallet M., Le Q.H., Mohty M., et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: A 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Exp Hematol 2008, 36:535-544.
11. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 2001, 98:2043-2051.
12. Kim J.G., Sohn S.K., Kim D.H., et al. Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2005, 35:489-495.
13. Helming A.M., Brand A., Wolterbeek R., et al. ABO incompatible stem cell transplantation in children does not influence outcome. Pediatr Blood Cancer 2007, 49:313-317.
14. Stussi G., Muntwyler J., Passweg J.R., et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 30:87-93.
15. Erker C.G., Steins M.B., Fischer R.J., et al. The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation. Transfusion 2005, 45:1382-1390.
16. Blin N., Traineau R., Houssin S., et al. Impact of donor-recipient majorABO mismatch on allogeneic transplantation outcome according to stem cell source. Biol Blood Marrow Transplant 2010, 16:1315-1323.
17. Buckner C.D., Clift R.A., Sanders J.E., et al. ABO-incompatible marrow transplants. Transplantation 1978, 26:233-238.
18. Benjamin R.J., McGurk S., Ralston M.S., et al. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 1999, 39:179-187.
19. Bacigalupo A., Van Lint M.T., Occhini D., et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988, 45:1091-1094.
20. Gajewski J.L., Johnson V.V., Sandler S.G., et al. Areview of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. Blood 2008, 112:3036-3047.
21. Briemer M.E., Molne J., Norden G., et al. Blood group A and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and Secretor Status. Clinical Transplantation 2006, 82:479-485.
22. Daniels G. The molecular genetics of blood group polymorphism. Hum Genet 2009, 126:729-742.
23. Gehrie E.A., Cates J.M., Nian H., et al. Blood group A antigen expression on cardiac endothelium is highly individualized: Possible implications for transplantation. Carvasc Pathol 2013, 22:251-256.
24. Costanzo M.R., Dipchand A., Starling R., et al. The International Society of Heart and Lung Transplantation Guidelines for the Care of Heart Transplant Recipients. J Heart Lung Transplant 2010, 29:914-956.
25. Montgomery R.A., Locke J.E., King K.E., et al. ABO incompatible renal transplantation: A paradigm ready for broad implementation. Transplantation 2009, 87:1246-1255.
26. Tanabe M., Kawachi S., Obara H., et al. Current progress in ABO-incompatible liver transplantation. European Journal of Clinical Investigation 2010, 40:943-949.
27. Kobayashi T., Saito K. Aseries of surveys on assay for anti-A/B antibody by Japanese ABO-incompatible Transplantation Committee. Xenotransplantation 2006, 13:136-140.
28. Kumlein G., Wilpert J., Safwenberg J., Tyden G. Comparing the tube and gel techniques for ABO antibody titration, as performed in three European centers. Transplantation 2007, 84:S17-S19.
29. Cooper D.K.C. Clinical survey of heart transplantation between ABO blood group-incompatible recipients and donors. JHeart Transplant 1990, 9:376-381.
30. Rowley S.D. Hematopoietic stem cell transplantation between red cell incompatible donor-recipient pairs. Bone Marrow Transplant 2001, 28:315-321.
31. Worel N., Greinix H.T., Schneider B., et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: A major ABO mismatch means problems. Transfusion 2000, 40:543-550.
32. Griffith L.M., McCoy J.P., Bolan C.D., et al. Persistence of recipient plasma cells and anti-donor isohemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopietic cell transplantation. Br J Haematol 2005, 128:668-675.
33. Barge A.J., Johnson G., Witherspoon R., Torok-Storb B. Antibody-mediated marrow failure after allogeneic bone marrow transplantation. Blood 1989, 74:1477-1480.
34. Slavin S., Nagler A., Naparstek E., et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
35. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
36. Bardos A., Tricot G., Toor A., et al. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 2002, 45:205-209.
37. Volin L., Ruutu T. Pure red-cell aplasia of long duration after major ABO-incompatible bone marrow transplantation. Acta Haematol 1990, 84:195-197.
38. Taniguchi S., Yamasaki K., Shibuya T., et al. Recombinant human erythropoietin for long-term persistent anemia after major ABO incompatible bone marrow transplantation. Bone Marrow Transplant 1993, 12:423.
39. Santamaría A., Sureda A., Martino R., et al. Successful treatment of pure red cell aplasia after major ABO-incompatible T cell-depleted bone marrow transplantation with erythropoietin. Bone Marrow Transplant 1997, 20:1105-1107.
40. Bavaro P., Di Girolamo G., Olioso P., et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation. Br J Haematol 1999, 104:930-931.
41. Sorà F., De Matteis S., Piccirillo N., et al. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation. Transfusion 2005, 45:643-645.
42. Ozkurt Z.N., Yegin Z.A., Yenicesu I., et al. Impact of ABO-incompatible donor on early and late outcome of hematopoietic stem cell transplantation. Transplantation Proceedings 2009, 41:3851-3858.
43. Bensinger W.I., Buckner C.D., Sander J.E., et al. ABO-incompatible marrow transplants. Transplantation 1982, 33:427-429.
44. Curley C., Pillai E., Mudie K., et al. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange. Transfusion 2012, 52:291-297.
45. Achermann F.J., Julmy F., Gilliver L.G., et al. Soluble type A substance in fresh-frozen plasma as a function of ABO and Secretor genotypes and Lewis phenotype. Transfus Apher Sci 2005, 32:255-262.
46. Stussi G., Halter J., Bucheli E., et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica 2009, 94:239-248.
47. Fong S.W., Qaqundah B.Y., Taylor W.F. Developmental patterns of ABO isoagglutinins in normal children correlated with the effects of age, sex, and maternal isoagglutinins. Transfusion 1974, 14:551-559.
48. Quillen K., Sheldon S.L., Daniel-Johnson J., et al. Apractical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 2011, 51:92-96.
49. Roback J.D., Grossman B.J., Harris T., Hillyer C.D. AABB Technical Manual 2011, AABB Press, Bethesda, MD. 17th ed.
50. Bolan C.D., Childs R.W., Procter J.L., et al. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001, 112:787-795.
51. Daniel-Johnson J., Schwartz J. How do I approach ABO-incompatible hematopoietic progenitor cell transplantation?. Transfusion 2011, 51:1143-1149.
52. Karafin M.S., Blagg L., Tobian A.A., et al. ABO antibodiy titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion 2012, 52:2087-2093.
53. Hareuveni M., Merchav H., Austerlitz N., et al. Donor anti-Jk(a) causing hemolysis in a liver transplant recipient. Transfusion 2002, 42:363-367.
54. Hows J., Beddow K., Gordon-Smith E., et al. Donor-derived red blood cell antibodies and immune hemolysis after allogeneic bone marrow transplantation. Blood 1986, 67:177-181.
55. Lee J.H., Gulbis A., De Padua Silva L., et al. Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant 2008, 42:67-69.
56. Zantek N.D., Koepsell S.A., Tharp D.R., Cohn C.S. The direct antiglobulin test: A critical step in the evaluation of hemolysis. Am J Hematol 2012, 87:707-709.
57. Lapierre V., Mahe C., Auperin A., et al. Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children. Transplantation 2005, 80:314-319.
58. Yazer M.H., Triulzi D.J. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opinion in Hematology 2007, 14:664-670.
59. Cserti-Gazdewich C.M., Waddell T.K., Singer L.G., et al. Passenger lymphocyte syndrome with or without immune hemolytic anemia in all recipients of lungs from rhesus alloimmunized donors: Three new cases and a review of the literature. Transfus Med Rev 2009, 23:134-145.
60. Ramsey G. Red cell antibodies arising from solid organ transplants. Transfusion 1991, 31:76-86.
61. Worel N., Greinix H.T., Supper V., et al. Prophylactic red blood cell exchange for prevention of severe immune hemolysis in minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation after reduced-intensity conditioning. Transfusion 2007, 47:1494-1502.
62. Ting A., Pun A., Dodds A.J., et al. Red cell alloantibodies produced after bone marrow transplantation. Transfusion 1987, 27:145-147.
63. Abou-Elella A.A., Camarillo T.A., Allen M.B., et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995, 35:931-935.
64. Lopez A., de la Rubia J., Arriaga F., et al. Severe hemolytic anemia due to multiple red cell alloantibodies after an ABO-incompatible allogeneic bone marrow transplant. Transfusion 1998, 38:247-251.
65. Borge P.D., Stroka-Lee H., Schmid P., et al. Delayed Red Blood Cell Chimerism in an HSC Transplant for Sickle Cell Disease Associated with a Non-ABO Alloantibody. Transfusion 2010, 50(suppl). S155A. Abstract 262.
66. Young P.P., Goodnough L.T., Westervelt P., Diersio J.F. Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stemcell transplantation. Bone Marrow Transplant 2001, 27:1305-1310.
67. de La Rubia J., Arriaga F., Andreu R., et al. Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?. Transfusion 2001, 41:106-110.
68. Zupańska B., Zaucha J.M., Michalewska B., et al. Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation. Transfusion 2005, 45:16-20.
69. a after allogeneic PBPC transplantation. Transfusion 2000, 40:632-636.
70. Tormey C.A., Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009, 49(3):505-512.
71. Lee E.J., Schiffer C.A. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989, 29:384-389.
72. Klumpp T.R., Herman J.H., Innis S., et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 1996, 17:1035-1041.
73. Mair B., Benson K. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion 1998, 38:51-55.
74. Shanwell A., Ringden O., Wiechel B., et al. Astudy of the effect of ABO incompatible plasma in platelet concentrates transfused to bone marrow transplant recipients. Vox Sang 1991, 60:23-27.
75. International Standards for Cellular Therapy Product Collection, Processing and Administration, v 5.2. FACT-JACIE, Omaha, NE, 2012.